Abstract
Our previous kinetics studies demonstrate that the natural product galangin exhibits a high-affinity inhibition of 153 nM towards human cytochrome P450 1A2. However, much less is known about the inhibitory mechanism of galangin against 1A2. To better understand the inhibitory mechanism of galangin towards 1A2, a modeling study including molecular docking and molecular dynamics simulations was performed. The binding pattern after molecular dynamics simulations reveals that galangin represents a similar binding pattern as another strong inhibitor α-naphthoflavone with a few exceptions. The O7 atom of galangin forms an H-bond with the O atom of Asn312. An intramolecular H-bond is observed between the O5 and O4 atoms of galangin. Energetic analysis indicates that galangin exhibits a less negative predicted binding free energy of -22.61 kcal/mol than α-naphthoflavone (-23.54 kcal/mol), which is consistent with inhibitory experiment (153 nM and 49 nM). Additionally, our results suggest that the inhibitory mechanism of galangin is mainly dominated by electrostatic/H-bond and hydrophobic/van der Waals interactions. The present work also revealed that the additional 4' hydroxyl group at the B ring would weaken the intermolecular interactions between kaempferol and 1A2, which was validated by our kinetics experiment (IC50 = 1 490 nM).
Keywords: Galangin, CYP 1A2, Inhibition, MD stimulations, Binding free energy
Letters in Drug Design & Discovery
Title: Molecular Insight into the Inhibitory Mechanism of Galangin Towards Human Cytochrome P450 1A2. A Modeling Study
Volume: 8 Issue: 3
Author(s): Yunyun Chen, Guo-Wen Chen and Hai-Bin Luo
Affiliation:
Keywords: Galangin, CYP 1A2, Inhibition, MD stimulations, Binding free energy
Abstract: Our previous kinetics studies demonstrate that the natural product galangin exhibits a high-affinity inhibition of 153 nM towards human cytochrome P450 1A2. However, much less is known about the inhibitory mechanism of galangin against 1A2. To better understand the inhibitory mechanism of galangin towards 1A2, a modeling study including molecular docking and molecular dynamics simulations was performed. The binding pattern after molecular dynamics simulations reveals that galangin represents a similar binding pattern as another strong inhibitor α-naphthoflavone with a few exceptions. The O7 atom of galangin forms an H-bond with the O atom of Asn312. An intramolecular H-bond is observed between the O5 and O4 atoms of galangin. Energetic analysis indicates that galangin exhibits a less negative predicted binding free energy of -22.61 kcal/mol than α-naphthoflavone (-23.54 kcal/mol), which is consistent with inhibitory experiment (153 nM and 49 nM). Additionally, our results suggest that the inhibitory mechanism of galangin is mainly dominated by electrostatic/H-bond and hydrophobic/van der Waals interactions. The present work also revealed that the additional 4' hydroxyl group at the B ring would weaken the intermolecular interactions between kaempferol and 1A2, which was validated by our kinetics experiment (IC50 = 1 490 nM).
Export Options
About this article
Cite this article as:
Chen Yunyun, Chen Guo-Wen and Luo Hai-Bin, Molecular Insight into the Inhibitory Mechanism of Galangin Towards Human Cytochrome P450 1A2. A Modeling Study, Letters in Drug Design & Discovery 2011; 8 (3) . https://dx.doi.org/10.2174/157018011794578150
DOI https://dx.doi.org/10.2174/157018011794578150 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Novel Hybrid Molecules of Isoxazole Chalcone Derivatives: Synthesis and Study of in vitro Cytotoxic Activities
Letters in Drug Design & Discovery Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Hybrid Imidazole-Pyridine Derivatives: An Approach to Novel Anticancer DNA Intercalators
Current Medicinal Chemistry Concise Synthesis of 1,1-Diarylvinyl Sulfones and Investigations on their Antiproliferative Activity <i>via</i> Tubulin Inhibition
Anti-Cancer Agents in Medicinal Chemistry Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology Most Recent Developments and Modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan Derivatives
Mini-Reviews in Medicinal Chemistry How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Formulation Development of Folic Acid Conjugated PLGA Nanoparticles for Improved Cytotoxicity of Caffeic Acid Phenethyl Ester
Pharmaceutical Nanotechnology Selected Heterocyclic Compounds as Antioxidants. Synthesis and Biological Evaluation
Current Topics in Medicinal Chemistry Analysis of DNA Microarray Data
Current Topics in Medicinal Chemistry Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
Current Drug Metabolism Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Extracts of <i>Anogeissus leiocarpus and Dillenia indica</i> Inhibit the Growth of MCF-7 Breast Cancer and COV434 Granulosa Tumor Cells by Inducing Apoptosis and Autophagy
Current Bioactive Compounds